INTRODUCTION

This revised UK VHP framework is based on published evidence and guidelines (Moureau et al, 2012, Hallam et al, 2016). Evaluation studies of the original VHP Framework to date have included the uptake of the VHP Framework (Burnett et al, 2018) and a small-scale pilot study exploring the impact of using the framework on the insertion and management of VADs (Weston et al, 2017).

The framework has been developed to facilitate a complex adaptive systems approach to VAD insertion and manage and is intended for adult vascular access in acute or planned settings. Whilst the principles of VHP should be incorporated into any emergency situation, it is recognised that other issues may take priority dependent on the condition of the patient and availability vascular access expertise therefore other immediate routes of access may be more appropriate e.g.

The evidence for each of the sections with references and signposting to further information can be accessed via the

Vessel Health and Preservation: The Right Approach for Vascular Access edited by Nancy Moureau, is available on open access https://www.springer.com/f-book/9783030031480

GLOSSARY OF TERMS

CVAD – Central vascular access device

CVC – Central venous catheter

Midline - Long venous catheter inserted into arm veins which

IV - Intravenous route of access
PICC – Peripherally inserted central venous catheter
PIVC – Peripheral intravenous catheter
Tunnelled CVC - central venous catheter which is tunnelled

away from exit site and has anchoring cuff **VAD** - Vascular access device

VHP - Vessel health and preservation

REFERENCES

Burnett, E., Hallam, C., Curran, E. et al. (2018) Vessel Health and Preservation Framework: Use of the outcome logic model for evaluation. Journal of Infection Prevention, 19, pp.228-234

Chopra, V., Flanders, S.C., Saint, S. et al. (2015) The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): Results from a Multispecialty Panel Using the RAND/UCLA Appropriateness Method. Annals of Internal Medicine, 15

Hallam, C., Weston, V., Denton, A., Hill, S., Bodenham, A., Dunn, H., Jackson, T. (2016) Development of the UK Vessel Health and Preservation (VHP) framework: a multi-organisational collaborative. Journal of Infection Prevention, 17, pp.65–72

Loveday, H.P., Wilson, J.A., Pratt, R.J. et al. (2014). Epic3: National Evidence – Based Guidelines for Preventing Health-care-Associated Infections in NHS Hospitals. Journal of Hospital Infection, S86, ppS1-S70

Moureau, N.L., Trick, N., Nifong, T. et al. (2012). Vessel health and preservation (Part 1): a new evidence-based approach to vascular access selection and management. Journal of Vascular Access, 13, pp.351–356

Ray-Barruel, G., Cooke, M., Chopra, V., Mitchell, M., Rickard, C. M. (2020). The I-DECIDED clinical decision- making tool for peripheral intravenous catheter assessment and safe removal: a clinimetric evaluation. BMJ Open, 10, pp.1-20. Downloaded from https://bmjopen.bmj.com/content/bmjop-en/10/1/e035239.full.pdf Last accessed March 2020

Royal College of Nursing (RCN). (2016). Standards of Infusion therapy 4th Edition RCN. London


Taxbro, K., Hammarskjöld, F., Thelin, B. et al. (2019) Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: an open-label, randomised, two-centre trial. British Journal of Anaesthesia,

van Loon, F., van Hooff, L., de Boer, H. (2019) The Modified A-DIVA Scale as a Predictive Tool for Prospective Identification of Adult Patients at Risk of a Difficult Intravenous Access: A Multicenter Validation Study. Journal of Clinical Medicine, 8,

Weston, V., Nightingale, A., O'Loughlin, C. et al. (2017) The implementation of the Vessel Health and Preservation framework. British Journal of Nursing (IV Therapy Supplement), 26, pp.18-22

UK VESSEL HEALTH AND PRESERVATION 2020

RIGHT LINE DECISION TOOL



Not 4-6 weeks suitable for -14 days - Ultrasound guided PIVC/Midline Use may be extended beyond the recommended time if **no complications** are noted and still clinically indicated (see daily evaluation tool). 'Ultrasound guided PIVC/Midline is preferable for

If Peripheral Vein grade not compatible with intended treatment

DURATION OF ANTICIPATED THERAPY? >4 weeks ->6 days -6 months¹ <14 days 1 Tunnelled CVC

CVC or alternative

Chopra et al (2015) ²Loveday et al (2014)

SECONDARY QUESTIONS

Secondary questions which may refine line choice in individual patients:

- Patient preference: lifestyle issues and/or body image.
- Known abnormalities of vascular anatomy which limit access site.
- Therapy specifics: e.g. intermittent vs continuous therapy, extreme duration of therapy (months-years) specific indications (e.g. bone marrow transplant).
- Local availability of vascular competency.
- Need for long term dialysis with: AV fistula, avoid vein damage from PICC or Axillary/Subclavian catheters.
- Relevant past medical history: coagulopathy, severe respiratory

dysfunction and other contra-indications to central access.

• Patient factors: e.g. cognitive function.

The risk benefits of individual device choice are starting to be challenged in large clinical trials³ with other studies in progress

³Taxbro et al (2019)

SUITABILITY OF MEDICINES

The most important principle to use when assessing suitability for an infusion to be administered via a peripheral intravenous catheter (PIVC) is that **ALL** intravenous medicines potentially pose a

In broad terms the safety of a medicine infusion to prevent damage to the vessel will relate to factors such as:

Does the patient still need IV therapy?

Consider has the device been used in the last 24 hours, or unlikely to be used in the nex

YES

Assessment decision tool for evaluation of vascular access device (VAD) ^{8,9}

2. Are there any complications present?
(Any signs of VAD related infection; pain score ≥2/10⁷; leakage; infiltration; thrombosis; extravasation; change in VIP score)

B. Dressing and securement are there complications present? Signs of dislodgement; is the dressing intact; is the device secure?)

Are there problems with the functioning of the device? (Consider missed doses, ease of flushing, occlusion)

- Osmolarity
- Viscosity
- Volume of dilution
- Speed of infusion
- Size and fragility of the peripheral vein

A central vascular access device (CVAD) should be the preferred device to administer infusions of vesicant chemotherapy and parenteral nutrition.

For some infusions, use of a CVAD is the preferred or essential route, for example, vasoconstrictor medicines (e.g. adrenaline and noradrenaline).

Many medicines administered by IV injection have a high osmolarity. Diluting the injection with

sodium chloride 0.9% or glucose 5% before administration will reduce the osmolarity).


Note: The use of a CVAD is specified for some medicines in the Summary of Medicine Product Characteristics (SmPC). Where this is the case the recommendation should be followed.

See the Medusa website for more information http://medusa.wales.nhs.uk/Home.asp

DAILY EVALUATION

YES NO

YES NO



Referal process to be determined locally

The number of attempts for cannulation before escalation should be reflected in local policy

Ray-Barruel et al (2018) BLoveday et al (2014) **Teleflex**®



1. Refer to local policies on management of the VAD.

2. Consider whether identified complication implies failure of the VAD or need to remove it.

3. Evaluate if the VAD is still appropriate. If not reapply the VHP Decision Tool





If'NO' to all

of these



rmation evolved tha might affect the

propriateness of VAD for this patient?

Has the patient's

condition changed requiring alternate IV

Continue to use current

re-evaluate the on-going

need for the VAD on a daily basis ^{8,9} /or more

frequently as required.

© Copyright of this publication is jointly held by the Infection Prevention Society, National Infusion VHP 2020 to be reviewed June 2023. Please forward feedback to VHP@ips.uk.net and Vascular Access Society Medusa and Royal College of Nursing 2020